Guidance

Smallpox vaccine PGD template

PGD template for administering smallpox vaccine in response to monkeypox.mpox (monkeypox).

From:
UK Health Security Agency
Published
5 August 2022
Last updated
205 OctoberSeptember 20222023 — See all updates

Applies to England

Documents

Smallpox patient group direction (PGD) template

Ref: UKHSA gateway number GOV-13156 GOV-15210

MS Word Document, 160168 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.ukpublications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This patient group direction (PGD) template supports the administration of the smallpox vaccine, modified vaccinia virus Ankara - Bavarian Nordic (MVA-BN), to individuals identified for immunisation in response to monkeypox.mpox.

The smallpox PGD version 2.003.00 is valid from 1715 OctoberSeptember 20222023 to 1615 OctoberSeptember 2023.2024.

For information:

  • at present, there are no stocks of the UK licensed MVA-BN vaccine Imvanex® available
  • the Medicines and Healthcare products Regulatory Agency (MHRA) have granted batch-specific variation for batchesbatch FDP00012number and FDP00072 toof the US licensed vaccine Jynneos®,Jynneos® inis view of the urgencyonly ofbatch theallowed need to manage the monkeypox outbreak – only vaccines from these 2 batches can be used under thethis UKHSA smallpox PGD

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012). Practitioners should follow local policy or procedures to access authorised PGD documents.

This PGD template should used with reference to current national recommendation on monkeypoxmpox vaccination, the Green Book and the Direct Healthcare Professional Communication letter from Bavarian Nordic the differences between Imvanex® brand (licensed in GB/UK)UK) and Jynneos® brand (licensed in US) of live modified vaccinia virus Ankara.

Published 5 August 2022
Last updated 205 OctoberSeptember 20222023 + show all updates

  1. Added version 3 - see page 2 for change history.

  2. Added version 2.00 – details of changes on page 2 and updated batch information.

  3. Corrected review date.

  4. First published.